Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-β and induce Tregs development via TGF-β

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Xu, Shuguang ^a   Zhu, Jingzhi ^a   Wu, Zhiyong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN DAB2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; DAB2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL STRAIN; CELL STRAIN SK BR 3; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 84898618337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091709     Document Type: Article

References (68)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, et al. (2000) Structure, sequence, and promoter analysis of human disabl (Pubitemid 32095437)
3. Zhou J, Hsieh JT (2001) The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 276:27793-27798.
4. Hocevar BA, Smine A, Xu XX, Howe PH (2001) The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 20:2789-2801. (Pubitemid 32938562)
5. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, et al. (2003) Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J 22:3084-3094. (Pubitemid 36758628)
6. Mayorga ME, Dong F, Sundararaman S, Huang Y, Jiang Y, et al. (2010) Central role for disabled-2 in mesenchymal stem cardiac protein expression and functional consequences after engraftment in acute myocardial infarction. Stem Cells Dev 20:681-693.
7. Martin JC, Herbert BS, Hocevar BA (2010) Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer 103:1716-1723.
8. Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX (1999) Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 18:3104-3113. (Pubitemid 29261231)
9. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, et al. (2002) The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 277:12622-12631. (Pubitemid 34952621)
10. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT (1998) Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 139:3542-3553. (Pubitemid 28512312)
11. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, et al. (1998) DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 17:419-424. (Pubitemid 28395905)
12. Massague J (2008) TGFbeta in Cancer. Cell 134:215-230.
13. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, et al. (2004) Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 173:6526-6531. (Pubitemid 39541034)
14. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700. (Pubitemid 36724933)
15. Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783-2810. (Pubitemid 41739965)
16. Hayes S, Chawla A, Corvera S (2002) TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol 158:1239-1249.
17. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL (2003) Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5:410-421. (Pubitemid 36592263)
18. Mitchell H, Choudhury A, Pagano RE, Leof EB (2004) Ligand-dependent and - independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell 15:4166-4178. (Pubitemid 39122020)
19. Bonifacino JS, Traub LM (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 72:395-447. (Pubitemid 36930451)
20. Hicke L, Dunn R (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19:141-172. (Pubitemid 37487346)
21. Dore JJ Jr, Yao D, Edens M, Garamszegi N, Sholl EL, et al. (2001) Mechanisms of transforming growth factor-beta receptor endocytosis and intracellular sorting differ between fibroblasts and epithelial cells. Mol Biol Cell 12:675-684. (Pubitemid 33052020)
22. Chen YG (2009) Endocytic regulation of TGF-beta signaling. Cell Res 19:58-70.
23. Clarke DC, Brown ML, Erickson RA, Shi Y, Liu X (2009) Transforming growth factor beta depletion is the primary determinant of Smad signaling kinetics. Mol Cell Biol 29:2443-2455.
24. Traub LM (2003) Sorting it out: AP-2 and alternate clathrin adaptors in endocytic cargo selection. J Cell Biol 163:203-208. (Pubitemid 37363120)
25. Morris SM, Cooper JA (2001) Disabled-2 colocalizes with the LDLR in clathrincoated pits and interacts with AP-2. Traffic 2:111-123. (Pubitemid 32219864)
26. Penheiter SG, Singh RD, Repellin CE, Wilkes MC, Edens M, et al. (2010) Type II transforming growth factor-beta receptor recycling is dependent upon the clathrin adaptor protein Dab2. Mol Biol Cell 21:4009-4019.
27. Pardali K, Moustakas A (2007) Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775:21-62. (Pubitemid 44881193)
28. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, et al. (1994) An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216:276-284. (Pubitemid 24076008)
29. Tong JH, Ng DC, Chau SL, So KK, Leung PP, et al. (2010) Putative tumoursuppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10:253.
30. Laiho M, Saksela O, Keski-Oja J (1987) Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 262:17467-17474. (Pubitemid 18032226)
31. Maxfield FR, McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5:121-132. (Pubitemid 38160255)
32. Grant BD, Donaldson JG (2009) Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol 10:597-608.
33. Pillai V, Ortega SB, Wang CK, Karandikar NJ (2007) Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 123:18-29. (Pubitemid 46401504)
34. Dalal BI, Keown PA, Greenberg AH (1993) Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143:381-389. (Pubitemid 24058193)
35. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, et al. (1994) Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 69:1006-1009. (Pubitemid 24161849)
36. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, et al. (1992) Localization of transforming growth factor-beta isotypes in lesions of the human breast. Hum Pathol 23:13-20.
37. Walker RA, Dearing SJ (1992) Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28:641-644.
38. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52:6949-6952. (Pubitemid 23006305)
39. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, et al. (2006) Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 371:191-193. (Pubitemid 44162899)
40. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, et al. (2008) Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112:335-341.
41. O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, et al. (2008) Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases. Biologics 2:563-569.
42. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, et al. (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74:492-501. (Pubitemid 27486505)
43. Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, et al. (2009) Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol 21:734-740.
44. Koumoundourou D, Kassimatis T, Zolota V, Tzorakoeleftherakis E, Ravazoula P, et al. (2007) Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2, N0 tumours. Anticancer Res 27:2613-2620. (Pubitemid 47227973)
45. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, et al. (2006) Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94:239-246. (Pubitemid 43151542)
46. Dumont N, Arteaga CL (2000) Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2:125-132. (Pubitemid 32223575)
47. Sigismund S, Confalonieri S, Ciliberto A, Polo S, Scita G, et al. (2012) Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev 92:273-366.
48. Vilar JM, Jansen R, Sander C (2006) Signal processing in the TGF-beta superfamily ligand-receptor network. PLoS Comput Biol 2:e3.
49. Zi Z, Feng Z, Chapnick DA, Dahl M, Deng D, et al. (2011) Quantitative analysis of transient and sustained transforming growth factor-[beta] signaling dynamics. Mol Syst Biol 7:492.
50. Polo S, Di Fiore PP (2006) Endocytosis conducts the cell signaling orchestra. Cell 124:897-900. (Pubitemid 43344231)
51. Massague J, Kelly B (1986) Internalization of transforming growth factor-beta and its receptor in BALB/c 3T3 fibroblasts. J Cell Physiol 128:216-222. (Pubitemid 16047931)
52. Zwaagstra JC, El-Alfy M, O'Connor-McCourt MD (2001) Transforming growth factor (TGF)-beta 1 internalization: modulation by ligand interaction with TGF-beta receptors types I and II and a mechanism that is distinct from clathrinmediated endocytosis. J Biol Chem 276:27237-27245.
53. Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, et al. (2002) Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J 21:4915-4926.
54. Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, et al. (2002) Myosin VI binds to and localises with Dab2, potentially linking receptormediated endocytosis and the actin cytoskeleton. Traffic 3:331-341. (Pubitemid 34461043)
55. Anders RA, Leof EB (1996) Chimeric granulocyte/macrophage colonystimulating factor/transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling. J Biol Chem 271:21758-21766. (Pubitemid 26303792)
56. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46-54. (Pubitemid 33741880)
57. Kenny PA, Lee GY, Bissell MJ (2007) Targeting the tumor microenvironment. Front Biosci 12:3468-3474.
58. Oluwadara O, Giacomelli L, Brant X, Christensen R, Avezova R, et al. (2010) The role of the microenvironment in tumor immune surveillance. Bioinformation 5:285-290.
59. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164.
60. Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30:636-645.
61. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, et al. (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746-1752.
62. Wang ZK, Yang B, Liu H, Hu Y, Yang JL, et al. (2011) Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 61:911-916.
63. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099. (Pubitemid 37022112)
64. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606-612. (Pubitemid 36182591)
65. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761. (Pubitemid 34921025)
66. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172:5149-5153. (Pubitemid 38542009)
67. Liu VC, Wong LY, Jang T, Shah AH, Park I, et al. (2007) Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883-2892. (Pubitemid 46333166)
68. Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, et al. (2009) Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol 183:3682-3689.